Skip to main content

Pain, Acute

5
Pipeline Programs
9
Companies
9
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
2
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 7 programs with unclassified modality

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Purdue Pharma
Purdue PharmaCT - Stamford
1 program
1
Methoxyflurane 3mLPhase 41 trial
Active Trials
NCT03868436Completed99Est. Sep 2020
Apsen Farmaceutica
Apsen FarmaceuticaBrazil - São Paulo
1 program
1
Fixed Dose CombinationPhase 31 trial
Active Trials
NCT03127592Terminated140Est. Jul 2022
Medical Developments International
1 program
1
MethoxyfluranePhase 31 trial
Active Trials
NCT03215056Completed192Est. Jun 2022
Aponia Laboratories
1 program
1
S-IbuprofenPhase 2Small Molecule1 trial
Active Trials
NCT03852459Completed251Est. Apr 2019
Lotus Pharmaceuticals
Lotus PharmaceuticalsTaiwan - Taipei
1 program
1
CT-044Phase 11 trial
Active Trials
NCT04252833Completed10Est. Mar 2020
Bayer
BayerLEVERKUSEN, Germany
1 program
Digital Pain Reduction KitN/A1 trial
Active Trials
NCT03187132Completed245Est. May 2020
Autonomous Therapeutics
1 program
Pain MeasurementN/A1 trial
Active Trials
NCT03330496Completed43Est. Mar 2022
Trevena
TrevenaPA - Chesterbrook
1 program
TRV130 1.5 mgPHASE_11 trial
Active Trials
NCT02083315Completed30Est. Aug 2013
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
IbuprofenPHASE_4Small Molecule1 trial
Active Trials
NCT04630834UnknownEst. Jun 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
City TherapeuticsIbuprofen
Purdue PharmaMethoxyflurane 3mL
Apsen FarmaceuticaFixed Dose Combination
Medical Developments InternationalMethoxyflurane
Aponia LaboratoriesS-Ibuprofen
Lotus PharmaceuticalsCT-044
TrevenaTRV130 1.5 mg
BayerDigital Pain Reduction Kit
Autonomous TherapeuticsPain Measurement

Clinical Trials (9)

Total enrollment: 1,010 patients across 9 trials

NCT04630834City TherapeuticsIbuprofen

Ibuprofen Plus Acetaminophen for Enhanced Pain Reduction

Start: Mar 2021Est. completion: Jun 2022
Phase 4Unknown
NCT03868436Purdue PharmaMethoxyflurane 3mL

PENTHROX™ in the Canadian Emergency Department (ED)

Start: Apr 2019Est. completion: Sep 202099 patients
Phase 4Completed
NCT03127592Apsen FarmaceuticaFixed Dose Combination

Phase III Efficacy and Tolerability Trial of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus Isolated Active Substances in Pain Control After Impacted Third Molar Extraction

Start: Oct 2020Est. completion: Jul 2022140 patients
Phase 3Terminated
NCT03215056Medical Developments InternationalMethoxyflurane

Methoxyflurane Analgesia for Paediatric Injuries

Start: Aug 2017Est. completion: Jun 2022192 patients
Phase 3Completed
NCT03852459Aponia LaboratoriesS-Ibuprofen

Controlled Study to Assess the Efficacy and Safety of S-Ibuprofen Topical Gel 5% (AP0302) in the Treatment of DOMS

Start: Jan 2018Est. completion: Apr 2019251 patients
Phase 2Completed
NCT04252833Lotus PharmaceuticalsCT-044

Open-label, Crossover, Food Effect Study to Evaluate CT-044 in Healthy Human Volunteers

Start: Feb 2020Est. completion: Mar 202010 patients
Phase 1Completed
NCT02083315TrevenaTRV130 1.5 mg

Pharmacokinetics and Pharmacodynamics of TRV130, Morphine, and Placebo in Healthy Subjects

Start: Jul 2013Est. completion: Aug 201330 patients
Phase 1Completed
NCT03187132BayerDigital Pain Reduction Kit

Development and Validation of a Digital Pain-Reduction Kit for Musculoskeletal Injuries

Start: Apr 2018Est. completion: May 2020245 patients
N/ACompleted
NCT03330496Autonomous TherapeuticsPain Measurement

Assessment of Pain in Newborns and Older Infants (Infant Pain Assessment Study =

Start: Oct 2017Est. completion: Mar 202243 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.